Fiztasovimab  (Synonyms: NPC-21; EV2038)

Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV^[1].

Human IgG1 lambda1

Human IgG1 lambda1, Isotype Control

Human

Fiztasovimab is isolated from Epstein-Barr virus-transformed peripheral B cells of a healthy donor^[1].
Fiztasovimab has a broadly neutralizing activity against 4 laboratory strains (AD169, Towne, Davis, Merlin) and 42 Japanese clinical isolates, which included GCV-resistant isolates^[1].
Fiztasovimab shows anti-hMCV activities in MRC-5 human embryonic fibroblast cells and human adult retinal pigment epithelial cells with IC₅₀s of 13-105 ng/mL and IC₉₀s of 0.208-1.026 μg/mL^[1].
Fiztasovimab also inhibits cell-to-cell infection by hCMV isolates in adult retinal pigment epithelial cells with IC90s of 13-19 μg/mL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.49 kDa

2467411-25-0

Liquid

Colorless to light yellow

[Fiztasovimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 lambda

• 
  Immobilized Human cytomegalovirus (HCMV) Glycoprotein B/gB Protein can bind Fiztasovimab. The EC₅₀ for this effect is 20.15 ng/mL.

• [1]. Furihata K, et al. Pharmacokinetics, Safety, and Tolerability of NPC-21, an Anti-Cytomegalovirus Monoclonal Antibody, in Healthy Japanese and White Adult Men: A Randomized, Placebo-Controlled, First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev. 2022 Jun;11(6):707-716.  [Content Brief]